Latest From Compugen Ltd.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
While Israel has not wanted for early-stage scientific excellence, leading lights in the country's biotech space are working to create an ecosystem where clinical, regulatory and managerial expertise can develop.
There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets.
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals...
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Middle East
- Parent & Subsidiaries
- Compugen Ltd.
- Senior Management
Anat Cohen-Dayag, PhD, Pres. & CEO
Ari Krashin, CFO & COO
Oliver Froescheis, PhD, SVP, Corp. & Bus. Dev.
Henry Adewoye, MD, CMO
John Hunter, PhD, CSO
- Contact Info
Phone: (972) 3 765 8585
26 Harokmim St. Bldg D
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.